ALFA Shareholders Approve A Capital Increase Of Ps $7,952 Million
| . |
September 27: |
Notice of Rights Exercise |
| . |
October 7: |
Notice of Capital Increase, Preemptive Subscription Rights and Additional Rights of First Refusal |
| . |
October 8: |
Start of Preemptive Rights Period |
| . |
October 9: |
Ex-Rights Date |
| . |
October 22: |
End of Preemptive Rights Period |
| . |
October 28: |
Deadline for Indeval and ALFA to notify the number of shares assigned to shareholders, as applicable |
| . |
November 4: |
Share Payment Deadline |
The aforementioned notices and additional information related to the resolutions approved at the Extraordinary Shareholders' Meeting of ALFA will be available at: inquiries related to the subscription process, shareholders and their financial brokers may contact: href="/cdn-cgi/l/email-protection#f397968196909b9c80b3929f9592dd909c9edd9e8b" rel="nofollow" target="_blank">[email protected
About ALFA
ALFA is comprised mainly of two businesses with global operations: Sigma, a leading multinational food company, focuses on the production, marketing, and distribution of quality foods through recognized brands in Mexico, Europe, the United States, and Latin America. Alpek is one of the world's top producers of Polyester (PTA, PET, PET sheet and rPET), and the leader in the Mexican market for Polypropylene (PP) and Expandable Polystyrene (EPS). In 2023, ALFA reported revenues of Ps $291,207 million (US $16.4 billion), and EBITDA of Ps $24,783 million (US $1.4 billion). ALFA's shares are quoted on the Mexican Stock Exchange and on Latibex, the market for Latin American shares of the Madrid Stock Exchange. For more information, please visit
SOURCE ALFA, S.A.B. de C.V.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment